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1  | INTRODUC TION
Mast cells (MCs) are multifaceted cells of the immune system. They 
originate in the bone marrow and circulate as immature progenitors, 
after which they home into tissues where they mature under the 
influence of local growth factors such as stem cell factor and IL-3 
(Gurish & Austen, 2012). MCs are found as resident cells of most 
tissues of the body, albeit particularly abundant at sites close to the 
exterior, such as skin and mucosal surfaces of the lung and gut. A 
hallmark feature of MCs is their large content of secretory granules, 
which are densely packed with a variety of preformed mediators. 
These include histamine and other biogenic amines, serglycin pro-
teoglycans, growth factors, cytokines, lysosomal hydrolases as well 
as a number of MC-restricted proteases (“MC proteases”), the lat-
ter encompassing tryptases, chymases, and carboxypeptidase A3 
(CPA3) (Pejler, Rönnberg, Waern, & Wernersson, 2010; Wernersson 
& Pejler, 2014).
MCs can be activated in response to a variety of stimuli, includ-
ing antigen-induced cross-linking of IgE molecules bound to their 
high affinity receptor on the MC surface. In addition, MC activation 
can be accomplished by a wide array of other stimuli such as ana-
phylatoxins, engagement of pattern recognition receptors, and in 
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Abstract
Tryptase-positive mast cells populate melanomas, but it is not known whether 
tryptase impacts on melanoma progression. Here we addressed this and show that 
melanoma growth is significantly higher in tryptase-deficient (Mcpt6−/−) versus 
wild-type mice. Histochemical analysis showed that mast cells were frequent in the 
tumor stroma of both wild-type and Mcpt6−/− mice, and also revealed their presence 
within the tumor parenchyma. Confocal microscopy analysis revealed that tryptase 
was taken up by the tumor cells. Further, tryptase-positive granules were released 
from mast cells and were widely distributed within the tumor tissue, suggesting that 
tryptase could impact on the tumor microenvironment. Indeed, gene expression 
analysis showed that the absence of Mcpt6 caused decreased expression of numer-
ous genes, including Cxcl9, Tgtp2, and Gbp10, while the expression of 5p-miR3098 was 
enhanced. The levels of CXCL9 were lower in serum from Mcpt6−/− versus wild-type 
mice. In further support of a functional impact of tryptase on melanoma, recombi-
nant tryptase (Mcpt6) was taken up by cultured melanoma cells and caused reduced 
proliferation. Altogether, our results indicate a protective role of mast cell tryptase 
in melanoma growth.
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response to various ligands to the MRGPRX2 receptor (McNeil et 
al., 2015). When MCs are activated, they can respond by degranula-
tion, whereby the preformed contents of their granules are released. 
MC activation can also drive the synthesis of a number of additional 
compounds, such as prostaglandins and leukotrienes, as well as nu-
merous cytokines, chemokines, and growth factors (Galli, Nakae, & 
Tsai, 2005).
MCs are undoubtedly mostly known for their detrimental im-
pact in allergic conditions. However, they are also known to contrib-
ute in a variety of additional disorders. In particular, there is a vast 
documentation supporting an involvement of MCs in various ma-
lignancies (Marichal, Tsai, & Galli, 2013; Oldford & Marshall, 2015; 
Ribatti & Crivellato, 2009; Varricchi et al., 2017). In this respect, 
a large number of clinical studies have revealed that MCs show a 
strong tendency to accumulate at malignant lesions. Typically, MCs 
are most frequently found in the tumor stroma but they can also be 
found within the tumor parenchyma. Clinical studies have also ex-
amined the correlation between MC presence and clinical outcome, 
and these studies have often led to the conclusion that MC density 
is associated with a poor outcome (Marichal et al., 2013; Oldford 
& Marshall, 2015; Ribatti & Crivellato, 2009; Varricchi et al., 2017). 
However, there are also numerous occasions in which MC pres-
ence appears to associate with good outcome (Marichal et al., 2013; 
Oldford & Marshall, 2015; Ribatti & Crivellato, 2009; Varricchi et 
al., 2017). Altogether, there is thus some controversy with regard to 
how MCs impact on cancer.
In melanoma, a number of clinical studies have revealed a strong 
accumulation of MCs (Ribatti, Ennas, et al., 2003; Ribatti, Vacca, et 
al., 2003; Siiskonen et al., 2015; Toth-Jakatics, Jimi, Takebayashi, & 
Kawamoto, 2000). To gain more mechanistic insight into the role of 
MCs in melanoma, we previously examined melanoma progression in 
wild-type (WT) mice versus mice that lacked connective tissue-type 
MCs altogether (Dudeck et al., 2011), using a model of melanoma col-
onization to the lung. In that study, we found that MCs had an overall 
detrimental impact (Öhrvik et al., 2016) and to dissect the underlying 
mechanism we assessed mice lacking all of the MC proteases in the 
same model. Strikingly, we found that mice with global MC protease 
deficiency, contrary to the mice lacking MCs altogether, developed 
larger tumors than did WT mice (Grujic et al., 2017). This suggests 
that the combined action of the MC proteases serves a protective 
function in this model of melanoma, that is, despite the overall neg-
ative impact of MCs. Further, the data indicated that the protective 
function of the MC proteases could be related to CXCL16/CD1d-
dependent effects on iNKT cell populations (Grujic et al., 2017).
Collectively, these findings indicate that MCs harbor both detri-
mental and protective activities with respect to tumor progression, 
and the overall impact of MCs may thus reflect the balance between 
such activities.
The aim of this study was to further dissect the impact of the 
MC proteases on melanoma progression. We thereby focused on 
tryptase, based on our previous observation that tryptase in cer-
tain settings can have an anti-proliferative action (Melo et al., 2017). 
For this purpose, we evaluated mice lacking tryptase Mcpt6 in a 
subcutaneous model of melanoma. Our findings reveal a protective 
function of tryptase in melanoma progression, hence shedding fur-
ther light into the role of MCs in tumor development.
2  | MATERIAL S AND METHODS
2.1 | Mice
WT and Mcpt6-deficient mice were all on C57BL/6J genetic back-
ground. Eight- to 16-wk-old mice were used in all experiments. All 
experiments were approved by the Local Ethics Committee (Uppsala 
djurförsöksetiska nämnd).
2.2 | Cells, tumor inoculation, and tissue collection
The cell line B16.F10 (ATCC; CRL-6475) was a gift from A.R. Thomsen 
(Copenhagen University, Denmark). Tumor cells were cultured in 
DMEM supplemented with 10% FBS, 1% L-glutamine, and 1% penicil-
lin and streptomycin solution. Prior to subcutaneous injections, cells 
reaching approximately 90%–100% confluency were trypsinized, re-
suspended in Hanks' balanced salt solution, and counted using trypan 
blue in order to adjust the cell concentration to 500,000 cells/ml. A 
total of 50,000 B16F10 cells (100 µl of cell suspension) were injected 
subcutaneously in the hip region (both sides). From day 7 post-injection 
and every two days, the mice were examined for tumor growth. The 
size of tumors (a-length, b-width, tumor volume = (axb2)/2) was deter-
mined with a caliper, and the mice were sacrificed when the tumor vol-
ume reached 1,100 mm3 (all mice within an experimental group were 
sacrificed when one of the animals reached a tumor volume of 1,100 
mm3). Blood was collected from B16F10 cell-injected and naïve mice 
into 1.5-ml microtubes and left to coagulate at room temperature for at 
least 1h. Blood samples were centrifuged at 2000g (4°C, 20 min), and 
serum was aliquoted and stored at −80°C for ELISA analysis. Tumors 
and inguinal lymph nodes were frozen on dry ice and stored at −80°C 
for gene array and qPCR analysis. Tumors were alternatively placed 
in 4% formalin (PBS-buffered) solution for histological analysis and 
immunohistochemistry.
Significance
Mast cells are known to be present in melanoma, but their 
role in tumor progression has not been clarified previ-
ously. Here we show that one of the enzymes expressed 
in large amounts by mast cells, tryptase, has a protective 
role in melanoma progression in a mouse model. Thereby, 
it is conceivable that modulation of tryptase function can 
represent a novel principle for interfering with melanoma 
growth.
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2.3 | Histochemistry and immunohistochemistry
Sections from paraffin-embedded tissue were deparaffinized and re-
hydrated, and epitope retrieval was performed by covering sections 
with 20 μg/ml of proteinase K in 50 mM Tris, pH 8.0, 1 mM EDTA, and 
0.5% Triton X-100 and incubated for 15 min at 37°C in a humidified 
chamber. Samples were brought to room temperature for 10 min, fol-
lowed by rinsing with PBS-T (10 mM phosphate buffer, pH 7.4, 2.7 mM 
KCl, 140 mM NaCl, and 0.1% Tween-20) and blocking for 10 min with 
Background Sniper solution (Biocare Medical, Pacheco, CA) at room 
temperature. Incubation with rabbit anti-CPA3 immune serum (1:500) 
(Rönnberg & Pejler, 2012) was performed overnight at 4°C, followed by 
addition of goat anti-rabbit Alexa 633 (1:1,000) at room temperature for 
1h. Rabbit anti-Mcpt6 immune serum (1:500) (Rönnberg & Pejler, 2012) 
was added overnight at 4°C, followed by incubation with goat anti-
rabbit Alexa 488 (1:1,000) at room temperature for 1h. Controls were 
prepared in parallel by using immune serum at the same concentration 
as the primary immune serum. Samples were extensively rinsed be-
tween all steps with PBS-T. ActinRedTM 555 and NucBlue probes were 
used according to the manufacturer's instructions (Life Technologies, 
Carlsbad, CA). Slides were prepared using SlowFadeTM diamond anti-
fade mounting medium (Invitrogen, Carlsbad, CA) and analyzed using 
a laser-scanning microscope equipped with ZEN 2009 software (LSM 
710; Carl Zeiss, Berlin, Germany). Staining of cultured B16F10 cells was 
performed as described (Rabelo Melo, Santosh Martin, Sommerhoff, & 
Pejler, 2019) Briefly, aliquots of 300 μl/well from 0.1∙106 B16F10 cells/
ml suspensions were cultured in 8 chamber polystyrene vessel tissue 
culture treated glass slides (Falcon, New York, NY) ± 50 nM recombi-
nant Mcpt6. After 24h, supernatants were removed and cells were fixed 
with 4% paraformaldehyde in PBS for 15 min. One hundred microliters 
of 50 μg/ml digitonin solution in PBS was added to each individual glass 
and incubated for 10 min at room temperature, followed by washing 
three times with TBS-T. The slides were treated with 300 μl of rabbit 
anti-Mcpt6 immune sera (1:500) (Rönnberg & Pejler, 2012) overnight 
(4°C), followed by incubation with goat anti-rabbit Alexa 488 (1:1,000) 
(Invitrogen, Rockford, IL) at room temperature for 1h. The slides 
were rinsed 3 × with TBS-T, and then, ActinRedTM 555 and NucBlue 
probes were added according to the manufacturer's instructions (Life 
Technologies, Carlsbad, CA). Slides were prepared using SlowFadeTM 
diamond antifade mounting medium (Invitrogen, Carlsbad, CA) and 
analyzed using a laser-scanning microscope equipped with ZEN 2009 
software (LSM 710; Carl Zeiss, Berlin, Germany).
2.4 | Recombinant Mcpt6 and EdU staining
Mcpt6 was produced in the mammalian cell line HEK293-EBNA with 
the vector pCEP-Pu2 according to previously published procedures 
(Hallgren, Karlson, Poorafshar, Hellman, & Pejler, 2000; Vernersson, 
Ledin, Johansson, & Hellman, 2002). The coding regions for full-
length enzymes containing an N-terminal 6-histidine purification tag 
and the proteins were purified from conditioned media from trans-
fected HEK293-EBNA cells on Ni-chelating IMAC agarose (Qiagen, 
Hilden Germany). Following activation cleavage, the enzyme was 
activated by adding heparin and lowering the pH as previously de-
scribed (Fu, Akula, Thorpe, & Hellman, 2019; Hallgren et al., 2000). 
EdU staining and flow cytometry were performed as described 
(Rabelo Melo et al., 2019).
2.5 | RNA extraction, quantitative RT-PCR 
(qPCR), and gene array analysis
Mice were euthanized, and tumors were collected, frozen on dry ice, 
and stored at −80°C until use. Tissues were homogenized in TRIzol 
reagent (Thermo Scientific, Wilmington, DE) using a polytron PT 1200 
(Kinematica AG, Luzern, Switzerland). The homogenate was centrifuged 
at 12,000 g for 1 min, and 500 µl of the supernatant (corresponding 
to ~50 mg tissue) was used for total RNA isolation using the Direct-zol 
RNA MiniPrep Kit (The Epigenetics Company, Irvine, CA). Total RNA 
concentration and purity were measured using a NanoDrop 1000 
F I G U R E  1   Mcpt6-deficient mice develop larger tumors than 
WT mice. (a) 50,000 B16F10 cells were injected subcutaneously 
in the hip region of WT and Mcpt6-deficient mice. From day 7 
post-injection and every two days, the mice were examined for 
tumor growth. Tumor volumes are presented as mean values ± SEM 
(n = 5–19). Note the larger volumes of tumors in Mcpt6-deficient 
versus WT mice on d.18 post-B16F10 injection. (b) Weight of 
tumors dissected after termination of the experiments. Note the 
larger mass of tumors from Mcpt6−/− versus WT mice. Tumor mass 
is presented as mean values ± SEM (n = 24–26). **p ≤ .01
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Spectrophotometer (Thermo Scientific, Wilmington, DE) and the ND-
1000 V3.7.0 program. First-strand cDNA was synthesized using up 
to 1 µg of total RNA as template and the iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA), following the manufacturer's instructions, 
on a SimpliAmp Thermal Cycler instrument (Applied Biosystems by 
Life Technologies/Thermo Fisher Scientific, Darmstadt, Germany). 
Subsequently, qPCR was performed using up to 100 ng cDNA, 400 nM 
primers (indicated in Supporting Table S1) and iTaq Universal SYBR 
Green Supermix (Bio-Rad, Hercules, CA), following the PCR cycling 
conditions recommended by the manufacturer, on the C1000 Touch 
Thermal Cycler instrument (Bio-Rad, Hercules, CA). Each sample was 
run in duplicates/triplicates, and qPCR data analysis was performed 
using the Bio-Rad CFX Maestro program. Gene expression levels were 
presented relative to the house keeping gene (glyceraldehyde 3-phos-
phate dehydrogenase; GAPDH) and relative either to WT inoculated 
mice or to respective non-inoculated naïve mice.
For analysis of miR3098 and miR669b, first-strand cDNA was 
synthesized using Qiagen miRCURY LNA RT kit (cat.# 339340) fol-
lowed by qPCR with the Qiagen miRCURY LNA SYBER Green PCR 
kit (cat.# 339345) and miRCURY LNA miRNA PCR assays (prim-
ers) specified in Supporting Table S1. qPCR samples were run in 
duplicates, and gene expression levels were presented relative to 
non-coding 5S-rRNA and relative to WT inoculated mice.
Gene array analysis was performed using Affymetrix GeneChip1 
expression arrays (GeneChip1 Mouse Gene 1.0 ST Array), as de-
scribed previously (Rönnberg, Guss, & Pejler, 2010).
2.6 | ELISA
Mouse CXCL9 ELISA (cat.# ab203364, Abcam, Cambridge, UK) and 
mouse IFNγ ELISA (cat.# BMS609, Thermo Scientific, Wilmington, 
DE) were performed with serum from naïve mice or from B16F10 
cell-injected mice. Absorbance was determined with a microplate 
reader: Tecan Infinite 200 (Tecan Austria, Grödig, Austria) and the 
Magellan V. 6.6 software.
2.7 | Statistical analysis
All analyses were performed in GraphPad Prism using two-tailed 
unpaired test, Mann–Whitney, 2-way ANOVA with Tukey's multiple 
comparison test (cell populations), multiple t test (cell populations), 
and unpaired t test (EdU labeling experiments, cell numbers). Results 
shown are either from representative experiments or represent col-
lected data from at least 2 independent experiments, presented 
F I G U R E  2   MCs are predominantly 
present in the tumor stroma. Tumors 
were paraffin-embedded, sectioned, 
and stained with toluidine blue. (a) 
Representative images showing the 
presence of toluidine blue-positive MCs 
(marked by arrows) both in the tumor 
stroma (S) and in the tumor parenchyma 
(P) (red dashed line separating P and S 
areas). Inserts show a higher magnification 
of toluidine blue-stained MCs. Original 
magnification × 200; bars = 100 µm. 
(b) Quantification of toluidine blue-
positive MCs. Numbers of MCs/mm2 
are presented as mean values ± SEM 
(n (tumor) = 5); **p ≤ .01. Note that the 
majority of the MCs were detected in 
the tumor stroma and that tumors from 
WT and Mcpt6−/− mice had comparable 
numbers of MCs. (c) Numbers of MCs 
showing signs of degranulation in tumors 
from WT and Mcpt6−/− mice. *p ≤ .05
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as mean values ± SEM. A p value ≤ .05 was considered statistically 
significant.
3  | RESULTS
3.1 | Tumors develop more rapidly in Mcpt6−/− than 
in WT mice
To study the impact of tryptase on tumor progression, we injected 
melanoma cells (B16F10) into the flanks of WT and tryptase null 
(Mcpt6−/−) mice. Tumor progression was then followed. As seen in 
Figure 1a, palpable tumors appeared starting from day ~7 in both 
WT and Mcpt6−/− mice. However, the tumors developed markedly 
more rapidly in Mcpt6−/− mice in comparison with WT controls, as 
quantified by continuous measurements of tumor volume in live ani-
mals. An increased tumor size in Mcpt6−/− versus WT animals was 
confirmed after dissecting out and weighing the tumors (Figure 1b).
3.2 | MCs are present in the stroma of 
subcutaneous melanoma tumors
To approach how MCs impact on the subcutaneous melanoma tu-
mors, we first assessed the presence and location of MCs in the tu-
mors. To identify MCs, we used toluidine blue staining. As seen in 
F I G U R E  3   Melanoma-associated MCs 
are of connective tissue subtype and 
release tryptase-containing granules to 
the tumor microenvironment. Confocal 
microscopy analysis of tumors from 
WT and Mcpt6−/− mice. (a) 3D images 
generated from z-stack tumor sections of 
WT mice showing the presence of MCs 
in the tumor stroma and parenchyma. 
The upper panels show Mcpt6 and 
CPA3 staining together, and the lower 
panels show CPA3 staining only. MCs 
are indicated by white arrows. Examples 
of individual granules are indicated by 
orange arrows. Note that the majority 
of MCs granules are Mcpt6 and CPA3 
double-positive and are widely distributed 
within the tumor tissue. (b) Mcpt6 can be 
found within the nucleus of tumor cells. 
The left panel depicts translucent nuclear 
staining showing the presence of Mcpt6 
within the nucleus of tumor cells adjacent 
to MCs. The middle panel represents 
higher magnifications of the boxed 
regions in the left panel and highlights 
the nuclear localization of Mcpt6 within 
tumor cells (see also Supporting Video 
S1). In the right panel, the nuclear staining 
is shifted into solid blocks; note that the 
Mcpt6 signal thereby is lost (Supporting 
Video S1). (c) WT melanoma-associated 
MCs are double-positive for Mcpt6 
and CPA3, indicating that they are of 
connective tissue subtype. The lower 
panels depict staining for Mcpt6 in tumors 
from Mcpt6−/− mice; note that the Mcpt6 
staining is completely abolished, revealing 
that the staining is specific. Scale 
bars = 10 μm
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Figure 2a,b, MCs were indeed found in the tumors. Notably, they 
showed a preferential location to the tumor stroma but could also 
be found within the tumor parenchyma. As judged by the toluidine 
blue staining, a substantial fraction of the MCs showed signs of 
degranulation, indicating that MCs had been activated within the 
tumor setting (Figure 2c). Importantly, MCs were equally abundant 
in tumors formed in WT and Mcpt6−/− mice, indicating that the im-
pact of Mcpt6 on tumor growth is not associated with differential 
migration of MCs into the tumor (Figure 2). Moreover, as in WT 
mice, the MCs in tumors of Mcpt6−/− mice showed a preferential 
location to the tumor stroma as judged by toluidine blue staining 
(Figure 2).
3.3 | Melanoma-associated MCs express Mcpt6
In mice, MCs are subdivided into two major subclasses—mucosal 
type MCs (MMCs) and connective tissue-type MCs (CTMCs). 
MMCs express chymases only (Mcpt1, Mcpt2), whereas CTMCs 
express tryptases (Mcpt6, Mcpt7), chymases (Mcpt4, Mcpt5), and 
CPA3 (Pejler, Åbrink, Ringvall, & Wernersson, 2007; Pejler et al., 
2010). Since our data suggest that Mcpt6 has an impact on mela-
noma growth, we hypothesized that the tumor-associated MCs 
were of CTMC type, that is, expressing Mcpt6. Indeed, as shown 
by confocal microscopy analysis, the tumor-associated MCs in WT 
mice were strongly positive for Mcpt6 (Figure 3). They were also 
positive for CPA3, confirming that they were of CTMC subtype. As 
expected, MCs in tumors of Mcpt6−/− mice did not express Mcpt6 
protein. However, they showed CPA3 positivity, hence indicat-
ing that the tumor-associated MCs in Mcpt6−/− mice were also of 
CTMC subtype (Figure 3c). It was also notable that Mcpt6 and CPA3 
were released in granule-like structures from the MCs into the sur-
rounding milieu. Notably, most of the released granules were dou-
ble-positive for Mcpt6 and CPA3, suggesting that these proteases 
are present in the same types of granules (Figure 3a). Altogether, 
these findings indicate that the tumor-infiltrating MCs in both WT 
and Mcpt6−/− mice were of the CTMC subtype and that they release 
granule-contained proteases into the microenvironment.
3.4 | Mcpt6 is released from tumor-infiltrating 
MCs and enters melanoma cells
As judged by toluidine blue staining, the tumor-associated MCs 
were predominantly located in the tumor stroma and were poorly 
visible in the tumor parenchyma (Figure 2). However, when using 
confocal microscopy, MCs were more readily detected within the 
tumor parenchyma (Figure 3a). Similar to the MCs in the stroma, 
these MCs were double-positive for Mcpt6 and CPA3, indicat-
ing that they were of CTMC subtype. An intriguing observation 
was that Mcpt6 was released from the parenchymal MCs, and 
was widely spread within the tumor parenchyma. An assessment 
of the distance between released Mcpt6+ granules and tumor-as-
sociated MCs revealed that granules can be found up to ~40 µm 
from the closest located MCs within the tumor parenchyma and 
up to ~60 µm from the closest located MCs in the tumor stroma 
(Figure 4). Moreover, the confocal analysis suggested that the re-
leased Mcpt6 was in fact found inside the tumor cells, partially lo-
calized to the tumor cell nuclei (Figure 3b; Supporting Video S1). 
CPA3 was also released from the MCs populating the tumor paren-
chyma, although the extent of release and uptake into tumor cells 
was less pronounced (Figure 3b).
F I G U R E  4   Mcpt6+ granules can be 
found at a large distance from MCs in the 
tumor stroma and parenchyma. 3D images 
from Z-stack confocal sections of tumor 
stroma (a) and parenchyma (b) were used 
to measure the distance between Mcpt6+ 
granules and the closest located MC. (c) 
Distances between MCs and individual 
granules were measured in µm. Scale 
bars = 10 μm
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3.5 | Recombinant Mcpt6 is taken up by melanoma 
cells and causes reduced proliferation
To provide further mechanistic insight into how tryptase affects 
melanoma cells, we generated recombinant Mcpt6 and assessed how 
it affects cultured B16.F10 melanoma cells. As seen in Figure 5a,b, 
addition of recombinant Mcpt6 to the melanoma cells caused mor-
phological effects, as judged by an increase in the side scatter param-
eter upon flow cytometry analysis. To assess proliferation, we used 
EdU, a thymidine analogue. By using this approach, we found that 
recombinant Mcpt6 causes decreased EdU staining of the melanoma 
cells, both as regards the % of EdU+ cells and with regard to the mean 
fluorescence intensity of the EdU staining (MFI) (Figure 5c–e). Hence, 
this indicates that Mcpt6 causes reduced proliferation of the mela-
noma cells. Reduced melanoma cell proliferation after exposure to 
recombinant Mcpt6 was also supported by assessment of cell num-
bers (Figure 5f). To assess the potential physical interaction between 
recombinant Mcpt6 and the melanoma cells, we performed confocal 
microscopy analysis. This showed that the melanoma cells, after ex-
posure to recombinant Mcpt6, frequently were positive for Mcpt6 
and that Mcpt6 could be found both close to the cell membrane and 
in the cell interior (Figure 6). Together, these data indicate that re-
combinant Mcpt6 interacts with and is taken up by melanoma cells, 
and causes reduced melanoma cell proliferation.
F I G U R E  5   Mcpt6 inhibits proliferation 
of B16F10 cells. B16F10 melanoma cells 
were cultured for 48h in the presence 
of 50 nM recombinant Mcpt6. (a-b) 
Representative dot blots show gated 
alive cells and reveal that B16F10 cells 
exposed to Mcpt6 show enhanced 
granularity, presented by higher mean 
fluorescence intensity (MFI; SSC-1). 
(b) Quantification of SSC analysis. The 
data represent mean values ± SEM from 
one representative experiment (n = 3); 
unpaired t test; **p ≤ .01. (c-e) Cells 
were assessed for proliferation by EdU 
staining and flow cytometry analysis. (c) 
Merged representative histograms for 
the EdU staining. (d-e) Quantification of 
the EdU staining, given as % EdU+ cells 
(d) and MFI for the EdU staining (e). The 
data represent mean values ± SEM (n = 6 
[d]; n = 3 [e]); unpaired t test; *p ≤ .05, 
***p ≤ .001. (f) Quantification of cell 
numbers using a hemocytometer. Data 
are presented as mean values ± SEM, 
pooled from 2 independent experiments; 
analyzed with unpaired t test; **p ≤ .01
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3.6 | Mcpt6 affects gene expression in the tumors
To further address the mechanism behind the impact of Mcpt6 on 
tumor growth, we hypothesized that Mcpt6 might affect gene ex-
pression patterns in the tumors. This was prompted by our previous 
observations that Mcpt6 can have marked effects on gene expres-
sion in MCs (Melo et al., 2017). To evaluate this possibility, we pre-
pared RNA from multiple tumors of WT and Mcpt6−/− mice, pooled 
these, and subjected the samples to gene array analysis. Indeed, this 
screening suggested that a number of genes might be differently 
regulated in tumors from WT versus Mcpt6−/− mice (Supporting 
Tables S2 and S3). To verify and quantify these data, we performed 
qPCR analysis, by focusing on a number of genes of interest. These 
included the IFNγ-dependent genes Cxcl9, Gbp2, and Gbp10, as well 
as Tgtp2. qPCR analysis showed that all of these genes were signifi-
cantly higher expressed in WT versus Mcpt6−/− tumors. There was 
also a trend of higher Gbp2 expression in WT versus Mcpt6−/− tu-
mors. In contrast, the IFNγ gene was not differently expressed 
(Figure 7). The gene array screen also indicated that a number of 
microRNAs were differently regulated as a consequence of Mcpt6 
deficiency. Indeed, qPCR analysis confirmed that one of these, 5p-
miR3098, was significantly lower expressed in tumors from WT ver-
sus Mcpt6−/− mice (Figure 7). To verify the effect on Cxcl9 at the 
protein level, ELISA analysis was conducted. In agreement with the 
gene array and qPCR data, we found that CXCL9 levels were signifi-
cantly higher in serum from WT versus Mcpt6−/− mice (Figure 8). We 
also measured IFNγ levels in serum, but found no significant differ-
ence between WT and Mcpt6−/− animals (Figure 8).
Next, we used qPCR analysis to evaluate whether the absence of 
Mcpt6 affected different populations of tumor-infiltrating immune 
cells. This was assessed by analyzing for cell-specific markers: CD4 
(CD4 T cells), CD8 (CD8 T cells), F4/80 (macrophages), CD206 (type 
2-polarized macrophages), CD11c (type 1-polarized macrophages), 
CD19 (B cells), and CPA3 (MCs). However, none of these genes were 
differently regulated in tumors from WT versus Mcpt6−/− mice, indi-
cating that Mcpt6 does not affect the profile of immune cells infil-
trating the melanomas (Figure 9). As judged by the ΔCt values for the 
respective genes, type 2-polarized macrophages (CD206+) appeared 
to be abundant within the tumors.
4  | DISCUSSION
The bona fide role of MCs in malignancies is still enigmatic. Intriguingly, 
their role may vary considerably among different types of cancers and 
perhaps also in the various stages of a malignant condition (Varricchi 
F I G U R E  6   Recombinant Mcpt6 is 
taken up by melanoma cells. B16F10 
melanoma cells were cultured with or 
without 50 nM recombinant Mcpt6 
as indicated. After 24h, the cells were 
stained with anti-Mcpt6 antibody and 
were analyzed by confocal microscopy. 
Cells were co-stained using a nuclear 
marker (Hoechst 33342; blue) and an actin 
probe (ActinRed; red). The figure depicts 
representative images. White arrows 
indicate positive Mcpt6 staining. Note 
that Mcpt6 staining is seen at the cell 
surface and also in the cytoplasm (lower 
panel), the latter indicating uptake of 
Mcpt6. Note also that no positive staining 
is seen in the absence of added Mcpt6 
(control; left panels)
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et al., 2017). Clearly, since a profound MC accumulation is evident in 
essentially all investigated malignant settings (Marichal et al., 2013; 
Oldford & Marshall, 2015; Ribatti & Crivellato, 2009; Varricchi et al., 
2017), it is reasonable to assume that they indeed play a significant 
role. It is notable that MCs are often among the first types of immune 
cells that arrive at a malignant lesion (Dalton & Noelle, 2012; Oldford 
& Marshall, 2015), and we may thus envision that effects of MCs are 
of particular importance in the early phases of cancer development. 
However, MCs are consistently found also in fully developed cancers 
and are thereby likely to affect also late stages of malignant processes. 
As regards the mechanistic impact of MCs on cancer, a favored notion 
is that MCs can contribute by expressing cancer-driving pro-angio-
genic factors such as VEGF, FGF2, angiopoietin-1, and matrix metallo-
proteinases (Baram et al., 2001; Esposito et al., 2004; Imada, Shijubo, 
Kojima, & Abe, 2000; Nakayama, Yao, & Tosato, 2004; Ribatti, Vacca, 
et al., 2003; Toth-Jakatics et al., 2000). Indeed, a correlation be-
tween the MC expression of such factors and cancer progression has 
been noted (Ribatti, Vacca, et al., 2003; Toth-Jakatics et al., 2000). 
However, it remains to be demonstrated by using direct experimen-
tal approaches (e.g., MC-conditional deletion of the respective genes) 
that MCs affect malignant development by affecting angiogenesis.
In this study, we show that MC tryptase, Mcpt6, affects the out-
come in a subcutaneous model of melanoma. Our data indicate that 
Mcpt6, under the experimental conditions employed, has a protec-
tive role, which is in contrast with the more common view of MCs as 
detrimental players in melanoma and other cancers. However, it is 
notable that our findings are in line with a previous study where we 
showed that the collective absence of all of the proteases expressed 
by connective tissue-type MCs led to a higher colonization of lungs 
with melanoma cells following their i.v. administration (Grujic et al., 
2017). Moreover, our findings are consistent with clinical evidence in 
support of a correlation between MC protease expression and pro-
tection against melanoma (Crincoli et al., 2019; Siiskonen et al., 2015; 
Stieglitz et al., 2019). A protective role of MCs is also supported by a 
study where secreted MC mediators showed anti-proliferative effects 
on cultured melanoma cells, although the nature of the active MC me-
diator(s) was not revealed (Stieglitz et al., 2019).
An important issue is to define how MC tryptase exerts its pro-
tective function in melanoma. To address this, we first assessed 
whether MCs were present in the melanomas, as well their loca-
tion within the tumor and their phenotype. In agreement with many 
previous studies, our findings reveal that MCs are predominantly 
F I G U R E  7   Mcpt6 deficiency affects 
gene expression in melanoma tumors. 
Total RNA was isolated from tumors 
of WT and Mcpt6-deficient mice. 
Subsequently, total RNA was subjected 
to qPCR analysis of expression of Cxcl9, 
Tgtp2, Gbp10, Gbp2, and miR3098. 
Expression of genes was evaluated 
relative to either GAPDH (protein-
encoding genes) or 5S-rRNA (miRNAs), 
and normalized to WT mice. Note the 
increased expression of Cxcl9, Tgtp2, and 
Gbp10, and lower expression of miR3098 
in tumors from WT versus Mcpt6−/− 
mice. Results are presented as mean 
values ± SEM (n = 7–13); Mann–Whitney 
test. *p ≤ .05
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detected in the tumor stroma, but were more rare in the tumor 
parenchyma by conventional staining techniques. However, when 
instead using confocal microscopy assessment with an anti-Mcpt6 
antibody, we found that MCs were in fact relatively abundant also 
within the tumor parenchyma. An important implication of these 
data was also that the tumor-associated MCs, both in the stroma and 
within the parenchyma, express tryptase. Since they also expressed 
CPA3, this indicates that the tumor-associated MCs are of CTMC 
rather than MMC subtype. This is thus in agreement with a previous 
study where it was shown that the tumor-infiltrating MCs in glioblas-
toma were of CTMC type (Polajeva et al., 2011).
Another important observation, from both conventional and 
confocal microscopy assessment, was that the tumor-associated 
MCs frequently showed signs of degranulation, hence suggesting 
that they release their preformed granule compounds into the tumor 
microenvironment. Further, an intriguing observation was that 
tryptase-positive granules were widely distributed within the tumor, 
not only in the close vicinity to MCs. This suggests that MCs have 
the capacity to influence tumor cells that are located both in their 
close proximity but also at a larger distance. Clearly, this can explain 
why MCs, despite being relatively rare within tumors, can have an 
impact on the overall tumor progression.
Intriguingly, tryptase released from MCs in the tumor paren-
chyma was frequently found within the tumor cells, that is, indicat-
ing cellular uptake. This was also supported by our in vitro approach, 
F I G U R E  8   Higher levels of CXCL9 but not of IFNγ in serum of 
WT compared to Mcpt6−/− mice. 50,000 B16F10 cells were injected 
subcutaneously in the hip region of WT or Mcpt6−/− mice. After 
termination of the experiment, blood was collected. Blood was also 
collected from naïve WT and Mcpt6−/− mice. (a-b) Levels of CXCL9 
in serum from (a) B16F10-injected (n = 12) and (b) naïve (n = 11) 
mice, measured by ELISA. Note the higher levels of CXCL9 in serum 
from B16F10-injected WT versus Mcpt6−/− mice, whereas no 
differences in CXCL9 levels were seen between WT and Mcpt6−/− 
naïve mice. (c) IFNγ levels in serum from B16F10-injected WT and 
Mcpt6−/− mice, measured by ELISA (n = 12). Results are presented 
as mean values ± SEM; Mann–Whitney test. *p ≤ .05
F I G U R E  9   qPCR analysis of tumors for the expression of the 
cell-specific markers CD4, CD8, F4/80, CD11c, CD206, CD19, and 
CPA3. Total RNA was isolated from tumors of WT and Mcpt6−/− 
mice. Total RNA was subjected to qPCR analysis for expression 
of the CD4, CD8, F4/80, CD11c, CD206, CD19, and CPA3 genes. 
Gene expression was evaluated relative to GAPDH (housekeeping 
gene) and presented as 1/∆Ct. Note that the qPCR analysis 
indicated that all of these populations were equally represented 
in WT and Mcpt6−/− mice. Results are presented as mean 
values ± SEM (n = 9–11). **p ≤ .01; ****p ≤ .0001
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where it was revealed that recombinant Mcpt6 is taken up by cul-
tured melanoma cells. In an earlier study, we showed that Mcpt6 
can have an impact on gene expression in MCs (Melo et al., 2014) 
and we also showed recently that human tryptase impacts on gene 
expression in human melanoma cells (Rabelo Melo et al., 2019). 
Prompted by these findings, we evaluated whether Mcpt6 can af-
fect gene expression patterns within melanoma tumors. Indeed, we 
found that a number of genes were differently expressed in tumors 
lacking Mcpt6. Among these were genes associated with IFNγ sig-
naling, including Cxcl9 and the intracellular GTPase Gbp10. Increased 
Cxcl9 expression was also supported by protein analysis, revealing 
higher levels of CXCL9 protein in serum from WT versus Mcpt6−/− 
tumor-bearing animals. CXCL9 is implicated as a tumor suppressor, 
due to its ability to recruit CD8+ cells (Harlin et al., 2009). However, 
we did not see any apparent impact of Mcpt6 deficiency on CD8 
expression in the tumors, suggesting that any impact of CXCL9 on 
tumor progression may be explained by effects beyond its influence 
on CD8+ T-cell recruitment. To date, the role of mouse Gbp10, one 
of eleven members of the Gbp family, in tumor biology is unclear. 
However, in human cutaneous melanoma, several Gbp mRNAs are 
associated with favorable prognosis (Wang et al., 2018). Hence, the 
higher expression of Gbp10 in WT versus Mcpt6−/− mice may repre-
sent a protective function in melanoma development. We also found 
upregulated expression of an additional GTPase, Tgtp2, in WT ver-
sus Mcpt6-deficient animals. However, the role of Tgtp2 in tumor 
settings remains to be explored. We also found that the absence of 
Mcpt6 was associated with elevated expression of the micro RNA 
miR3098. Interestingly, miR3098 has previously been implicated in 
lung cancer (Wang, Xu, & Wang, 2017) and diabetes (Rubin, Salzberg, 
Imamura, Grivitishvilli, & Tombran-Tink, 2016), although the exact 
role miR3098 under these conditions has not been clarified.
To provide further mechanistic insight into how tryptase af-
fects the melanoma cells, we performed experiments in which the 
effect of recombinant Mcpt6 on cultured melanoma cells was as-
sessed. Interestingly, these analyses revealed that Mcpt6 caused 
a substantial decrease in the proliferation of the melanoma cells. 
Hence, a potential explanation for the elevated tumor progression 
seen in Mcpt6−/− versus WT animals in vivo could be that Mcpt6 lim-
its tumor cell proliferation. However, we cannot exclude that other 
mechanisms contribute to the effects of Mcpt6 deficiency on tumor 
progression in vivo. Of note, MCs express a variety of compounds 
of both potentially pro-tumorigenic and anti-tumorigenic nature 
(Marichal et al., 2013; Oldford & Marshall, 2015; Ribatti & Crivellato, 
2009; Varricchi et al., 2017). We may thus envision that the exact 
expression profile of MCs present in a given tumor setting may de-
termine their net impact on tumor growth. On a speculative angle, 
it is plausible that tumor-associated MCs may exhibit polarization 
into pro-tumorigenic (e.g., expressing high levels of pro-tumorigenic 
growth factors such as VEGF) and anti-tumorigenic subtypes (e.g., 
expressing high levels of tryptase), that is, in analogy with the polar-
ization seen in the macrophage niche. However, further investiga-
tions are needed to evaluate this hypothesis.
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